Research Progress on Mechanism of Shikonin in Treatment of Colitis
DOI:
https://doi.org/10.53469/jcmp.2024.06(10).34Keywords:
Shikonin, Colitis, Intestinal flora, Intestinal barrier, PKM2Abstract
Zicao, a traditional Chinese herbal medicine utilized in the clinical management of ailments such as soreness, eczema, burns from both water and fire, various forms of hemorrhage, among others. Shikonin, a naphthoquinone compound derived from the root of comfrey, exhibits properties including antioxidation, anti-inflammation, promotion of skin repair, free radical scavenging, and inhibition of lipid metabolism. Colitis is an inflammatory condition affecting the colon that can arise from diverse etiological factors including bacteria, fungi, viruses, parasites, protozoa and other organisms; its primary clinical manifestations encompass diarrhea, abdominal pain and mucus-laden stools. This condition often presents with recurrent episodes. The treatment for colitis predominantly relies on antibiotics and anti-inflammatory agents; however their long-term side effects are considerable. Therefore it is crucial to explore milder therapeutic alternatives. Recent studies have indicated that shikonin may effectively address colitis by elucidating its underlying mechanisms in this review paper aimed at providing a theoretical foundation for the treatment and recovery process associated with colitis.
References
GUO C, HE J, SONG X, et al. Pharmacological properties and derivatives of shikonin-A review in recent years [J]. Pharmacol Res, 2019, 149: 104463.
BRZYCKI NEWTON C, YOUNG E M, ROBERTS S C. Targeted control of supporting pathways in paclitaxel biosynthesis with CRISPR-guided methylation [J]. Front Bioeng Biotechnol, 2023, 11: 1272811.
WANG B, WU Z, WANG J, et al. Insights into the mechanism of Arnebia euchroma on leukemia via network pharmacology approach [J]. BMC Complement Med Ther, 2020, 20(1): 322.
YANG C, MERLIN D. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives [J]. Int J Nanomedicine, 2019, 14: 8875-89.
HAMMER T, LOPHAVEN S N, NIELSEN K R, et al. Dietary risk factors for inflammatory bowel diseases in a high-risk population: Results from the Faroese IBD study [J]. United European Gastroenterol J, 2019, 7(7): 924-32.
ZHU S, GUO Y, ZHANG X, et al. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics [J]. Cancer Lett, 2021, 503: 240-8.
CHEN J, XIE J, JIANG Z, et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 [J]. Oncogene, 2011, 30(42): 4297-306.
ZHAO X, ZHU Y, HU J, et al. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis [J]. Sci Rep, 2018, 8(1): 14517.
DODDAPATTAR P, DEV R, GHATGE M, et al. Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis [J]. Circ Res, 2022, 130(9): 1289-305.
HUANG B, WANG Q, JIANG L, et al. Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages [J]. Front Pharmacol, 2022, 13: 926945.
ZHANG D, TANG Z, HUANG H, et al. Metabolic regulation of gene expression by histone lactylation [J]. Nature, 2019, 574(7779): 575-80.
HAN X, DING S, JIANG H, et al. Roles of Macrophages in the Development and Treatment of Gut Inflammation [J]. Front Cell Dev Biol, 2021, 9: 625423.
MAO L, KITANI A, STROBER W, et al. The Role of NLRP3 and IL-1β in the Pathogenesis of Inflammatory Bowel Disease [J]. Front Immunol, 2018, 9: 2566.
ALI F E M, IBRAHIM I M, GHOGAR O M, et al. Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study [J]. World J Gastroenterol, 2023, 29(6): 1026-53.
WANG Q, ZHOU H, BU Q, et al. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis [J]. J Hepatol, 2022, 77(2): 312-25.
SHAO B Z, XU H Y, ZHAO Y C, et al. NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation [J]. Inflammation, 2023, 46(1): 35-46.
LOPES DE OLIVEIRA G A, ALARCóN DE LA LASTRA C, ROSILLO M, et al. Preventive effect of bergenin against the development of TNBS-induced acute colitis in rats is associated with inflammatory mediators inhibition and NLRP3/ASC inflammasome signaling pathways [J]. Chem Biol Interact, 2019, 297: 25-33.
HOLMER A K, SINGH S. Expanding targeted immune modulators in ulcerative colitis [J]. Lancet, 2021, 397(10292): 2313-5.
FENG J, WANG Y, LV Y, et al. XA pH-Responsive and Colitis-Targeted Nanoparticle Loaded with Shikonin for the Oral Treatment of Inflammatory Bowel Disease in Mice [J]. Mol Pharm, 2022, 19(11): 4157-70.
ANDúJAR I, MARTí-RODRIGO A, GINER R M, et al. Shikonin Prevents Early Phase Inflammation Associated with Azoxymethane/Dextran Sulfate Sodium-Induced Colon Cancer and Induces Apoptosis in Human Colon Cancer Cells [J]. Planta Med, 2018, 84(9-10): 674-83.
ANDúJAR I, RíOS J L, GINER R M, et al. Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice [J]. Evid Based Complement Alternat Med, 2012, 2012: 271606.
CHEN X, LIN S, LIANG Y, et al. Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects [J]. Naunyn Schmiedebergs Arch Pharmacol, 2023, 396(12): 3547-57.
NISHIDA A, INOUE R, INATOMI O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease [J]. Clin J Gastroenterol, 2018, 11(1): 1-10.
NISHIDA A, NISHINO K, SAKAI K, et al. Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease? [J]. World J Gastroenterol, 2021, 27(23): 3317-26.
KANG M, MARTIN A. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development [J]. Semin Immunol, 2017, 32: 3-13.
HANSEN J J. Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases [J]. Curr Allergy Asthma Rep, 2015, 15(10): 61.
MCCOY A N, ARAúJO-PéREZ F, AZCáRATE-PERIL A, et al. Fusobacterium is associated with colorectal adenomas [J]. PLoS One, 2013, 8(1): e53653.
KRAJINA T, LEITHäUSER F, MöLLER P, et al. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis [J]. Eur J Immunol, 2003, 33(4): 1073-83.
LIN H, MA X, YANG X, et al. Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer [J]. Int Immunopharmacol, 2022, 111: 109097.
CARDONA F, ANDRéS-LACUEVA C, TULIPANI S, et al. Benefits of polyphenols on gut microbiota and implications in human health [J]. J Nutr Biochem, 2013, 24(8): 1415-22.
PETERSON L W, ARTIS D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis [J]. Nat Rev Immunol, 2014, 14(3): 141-53.
SUN M, HE C, CONG Y, et al. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota [J]. Mucosal Immunol, 2015, 8(5): 969-78.
HU Y, YE Z, WU M, et al. Corrigendum: The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies [J]. Front Med (Lausanne), 2022, 9: 886105.
DI SABATINO A, SANTACROCE G, ROSSI C M, et al. Role of mucosal immunity and epithelial-vascular barrier in modulating gut homeostasis [J]. Intern Emerg Med, 2023, 18(6): 1635-46.
TORRES J, HU J, SEKI A, et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice [J]. Gut, 2020, 69(1): 42-51.
BARBARA G, BARBARO M R, FUSCHI D, et al. Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier [J]. Front Nutr, 2021, 8: 718356.
VAN DER POST S, JABBAR K S, BIRCHENOUGH G, et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis [J]. Gut, 2019, 68(12): 2142-51.
HAN H, SUN W, FENG L, et al. Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis [J]. PeerJ, 2021, 9: e10675.
NIKITA G, VIVEK P, CHHAYA G. Wound-healing activity of an oligomer of alkannin/shikonin, isolated from root bark of Onosma echioides [J]. Nat Prod Res, 2015, 29(16): 1584-8.
KARAYANNOPOULOU M, TSIOLI V, LOUKOPOULOS P, et al. Evaluation of the effectiveness of an ointment based on Alkannins / Shikonins on second intention wound healing in the dog [J]. Can J Vet Res, 2011, 75(1): 42-8.
HE Y, LUO K, HU X, et al. Antibacterial Mechanism of Shikonin Against Vibrio vulnificus and Its Healing Potential on Infected Mice with Full-Thickness Excised Skin [J]. Foodborne Pathog Dis, 2023, 20(2): 67-79.
IMAI K, KATO H, TAGUCHI Y, et al. Biological Effects of Shikonin in Human Gingival Fibroblasts via ERK 1/2 Signaling Pathway [J]. Molecules, 2019, 24(19).
SHU G, XU D, ZHANG W, et al. Preparation of shikonin liposome and evaluation of its in vitro antibacterial and in vivo infected wound healing activity [J]. Phytomedicine, 2022, 99: 154035.
ANDúJAR I, RECIO M C, BACELLI T, et al. Shikonin reduces oedema induced by phorbol ester by interfering with IkappaBalpha degradation thus inhibiting translocation of NF-kappaB to the nucleus [J]. Br J Pharmacol, 2010, 160(2): 376-88.
ANDúJAR I, RíOS J L, GINER R M, et al. Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells [J]. Eur J Pharm Sci, 2013, 49(4): 637-41.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mengmeng Zhang, Xuan Qu
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
